Carlyle and GTCR-backed Resonetics to acquire medical nitinol business from SAES for $900m.

Carlyle and GTCR-backed Resonetics, an engineering, product development, prototyping, and manufacturing solutions provider, to acquire medical nitinol business from SAES, an electronic component manufacturing company, for $900m. "We are excited to support the Resonetics management team as it executes on a high growth strategy to bolster its platform of differentiated capabilities to better serve customers. We believe Resonetics and the SAES Medical Nitinol business are highly complementary to each other and this combination, in our view, will result in an even stronger service offering to large medical technology companies across the world," Robert Schmidt, Carlyle Managing Director.